This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
The new manufacturing lines will be operational in phases, with existing lines at the Suzhou and Rewari sites already functional since Q4 2024, and additional lines expected to start operations by Q3 2025. Thanks to their favorable dissolution rates, these capsules are valuable for developers of medicines and nutraceuticals.
On 19 November 2024, Lupin announced that it had received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Extended-Release Capsules.
ACG Inspection is launching its Life Sciences Cloud in India at the CPHI IndiaPMEC India show, which had its US launch at the Pack Expo US 2024. What has been the response to the US launch in terms of clients who are inquiring from clients or clients who have signed up? The answer is all of the above.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish Felicity Thomas June 25th 2024 Podcast In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish. Poor API Quality Threatens a Healthy Supply. Pharmaceutical Technology 2025 49 (4). link] Thomas, F. PharmTech.com.
On 7 November 2024, the U.S. The committee reviewed new data regarding the oral administration of phenylephrine and unanimously concluded that the current scientific evidence does not support its effectiveness at the recommended OTC dosage. Theresa Michele, M.D.,
AMH Aged Care Companion - Contains information on managing more than 70 common conditions in the elderly, with a focus on issues relevant to older people using medicines.
Following the FDAs previous interchangeability designation for 20mg & 80mg prefilled syringes, YUFLYMA is now fully interchangeable with HUMIRA across all marketed dosage forms and strengths. HADLIMA was previously granted interchangeable status in June 2024 for low-concentration (40 mg/0.8 mL, 40 mg/0.8
As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. In March 2024, Lonza hosted its first digital Responsible Supplier Event which brought together more than 1,100 participants.
percent between 2024 and 2033. Packaging types generating demand in the market include tamper-proofing drug packaging against counterfeiting, as well as single-dosage packaging, according to the research. The worldwide pharmaceutical container packaging market is expected to rise in revenue from $104.12
5 Phase 3 ECHO Trial: A New Frontline Option The approval was supported by data from the phase 3 ECHO trial (NCT02972840), presented at the 2024 European Hematology Association Hybrid Congress. June 21, 2024. Deaths were reported in 5 TN and 6 R/R patients. The trial enrolled 598 patients 65 years or older with TN MCL. Hemasphere.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish Felicity Thomas June 25th 2024 Podcast In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
This phase 1b clinical trial, conducted between September 2023 and November 2024, was designed to build on promising preclinical data that demonstrated improved efficacy and tolerability with continuous SC lenalidomide delivery in murine MM models. It will be interesting to see what dosage form these data prompt the future development of.
FDA approvals dropped in May to 14 drugs after hitting 20 and above in the two months prior, but the total of 84 OKs so far in 2025 is the second only to 2024’s record high for the first part of the year, according to Clarivate. The FDA approved the updated formulation, which will be sold under the brand name Yeztugo, earlier this month.
Fixed-dose combinations (FDCs), which contain two or more active ingredients in a single dosage form, have seen a significant rise in production and usage across the pharmaceutical industry. More recently, in August 2024, another 156 FDCs, including widely used cold and fever medications, were prohibited due to safety concerns.
As per a Future Market Insights report, the global sustainable pharma packaging market size is projected to grow from $ 96 billion in 2024 to $ 410 billion by 2034, reflecting a 15.6 per cent CAGR. For example, consider a tablet of 13.5 mm length and 7.5 To pack 20 such tablets, pharma companies currently use 857.5
Animal studies reveal dose-dependent hepatic responses to CBD, supporting the need for cautious monitoring even at consumer-relevant dosages. Pharmacists should review patient medication profiles, advise on appropriate dosage adjustments, and monitor for cumulative toxicity. Published June 6, 2024. REFERENCES Minnerd J.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here. Subscribe Now!
Generics are exact chemical copies of small-molecule drugs, with identical active ingredients, strengths, dosage forms, and routes of administration. Updated June 20, 2024. 2024 US Generic & Biosimilar Medicines Savings Report. September 2024. REFERENCES 1. Accessed May 13, 2025. Biosimilar medicines: overview.
2 Guiding prescribers and patients through initiation of lumatperone, adjusting dosage amounts, and switching from other antipsychotics, emphasizing its favorable relapse reduction profile is key in preventing relapse.
This single-center, retrospective, observational study included data from electronic health records and specialty pharmacies from January 1, 2023, to June 1, 2024, with specialty pharmacy dispensing data specifically used to identify patients who had received Humira and a biosimilar during the study period.
A group of experts will present an encore abstract titled " Prevalence of Dosage Modifications and Impact on Response Milestone Among Patients With CML Treated With Imatinib Using Real-World Data " at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20.
He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360. Anti-Cancer Drugs. 2024.1389922.
The field is expanding into autoimmune diseases, with nononcology trials representing 51% of the pipeline by late 2024. Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ).
IPA also pointed out that US regulations require adverse events related to any dosage form of a drug to be reported under the same Abbreviated New Drug Application (ANDA) number, even if the product is manufactured at a different facility or outside India. Thus, it cannot be conclusively linked with the manufacturing site or manufacturers.
August 8, 2024. Updated January 19, 2024. LinkedIn Workplace Learning Report 2024. American Oncology Network. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development.
Over the past couple years, the demand for this RSV vaccine has continued to be high; in fact, Sanofi had announced in October 2023 that the extraordinary demand had caused shortages impacting the 2023-2024 season. As of now, supply for this coming season matches last year’s total dosage, with production expected to continue.
January 17, 2024. 2024;25(1):336. doi:10.1186/s13063-024-08174-x 7. Psychedelic Pharmacists Association is working to promote, establish the role of the pharmacist in psychedelic-assisted therapy. Pharmacy Times. Accessed May 16, 2025. About the PPA. Psychedelic Pharmacists Association. Accessed May 16, 2025.
By observing the microscopic effects of potential treatments, students will be able to gain insight into toxicity, dosage response, and disease progression. India Ranking in the Global Innova- tion Index 2024. 2024, December). 2024, August 27). References Pathak, R., Sachan, N., & Chandra, P. Malviya, P. link] dchem.4c01180
Drug Solutions Podcast: Growth and Advancements in Fill/Finish Felicity Thomas June 25th 2024 Podcast In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Last month, European Commission approved the new subcutaneous (SC) formulation of Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) with a dosage strength of 600 mg/vial, expanding treatment options for various adult solid tumours. Sign up for our daily news round-up! Give your business an edge with our leading industry insights.
Selection of an appropriate OTC analgesic should take into consideration various patient factors, including the patient’s overall health status, current medical conditions, and medication profile, as well as patient preferences, which are often influenced by dosage form, required dosing intervals, and cost of OTC medication. 2014.01.108 6.
One example is a canalicular gel device (Lacrifill, Nordic Pharma) introduced in June 2024 (7). 2024 11 (2), 179. Times 2024 49 (11). 2024 8 (5). Recent developments have helped address many of these issues. Seeing the Future: A Review of Ocular Therapy. DOI: 10.3390/bioengineering11020179 Chandel, A. and Kandav, G.
Steqeyma provides a new dosage form and strength, enhancing treatment flexibility for young patients with chronic inflammatory conditions. In December 2024, the FDA approved the biosimilar in 45-mg/0.5 The biosimilar demonstrated comparable efficacy and safety to Stelara in a phase 3 clinical trial, supporting its FDA approval.
CE hours from BCOP Updates 2024 and the Annual Conference 2025, featuring topics such as acute leukemia, cellular therapy for solid tumors, and the pharmacist’s role in serious illness conversations. HOPA has selected 4.0 Additional information is available here.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
EDQM has been promoting the use of alternative tests and removed the RPT in June 2024 from Ph. In July 2024, the United States Pharmacopeia (USP) announced it was permitting the use of non-animal-derived reagents for endotoxin testing (3).Susan July 26, 2024. Press Release. and Haigney, S. PharmTech.com. link] Haigney, S.
In May 2024, the US Food and Drug Administration (FDA) approved Moderna’s next-generation base-modified mRNA-lipid nanoparticle (LNP) respiratory syncytial virus (RSV) vaccine mRESVIA (mRNA-1345) in adults aged 60 years and older with lower respiratory tract disease (5). billion in 2024 and is forcasted to reach US$71.7 Mullard, A.
Sustainability efforts In other company news, Hikma published its 2024 Sustainability Report, detailing the company’s approach to sustainability. Hikma Publishes its 2024 Sustainability Report Reinforcing Commitment to Global Access to Medicines. Hikma Sustainability Report 2024. Mike Carey, R-Ohio, said in the release.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish Felicity Thomas June 25th 2024 Podcast In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
In a press release, Theramex estimated that more than 1000 postmenopausal women in Scotland would be eligible for treatment, with SMC’s recommendation following a previous one made in August 2024 by the National Institute for Health and Care Excellence (NICE) governing abaloparatide’s status in England, Wales, and Northern Ireland (1).
.” Dr Veeramani, Chairman, Pharmexcil, said “ The Indian pharmaceutical industry stands as a global leader, exporting to over 200 countries and providing comprehensive solutions across APIs, finished dosages, clinical research, and pharmacovigilance.
Factor Dosage (units) = (Desired level - Baseline level) x Weight (in kg) / k , where k is 2.0 External Links WFH Guidelines for the Management of Haemophilia, 2020 CPG Management of Haemophilia, 2018 Hemophilia Society of Malaysia Publications Haemophilia Foundation Australia - Haemophilia Booklet, 2024
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content